172 related articles for article (PubMed ID: 33753596)
1. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
Hirbe AC; Eulo V; Moon CI; Luo J; Myles S; Seetharam M; Toeniskoetter J; Kershner T; Haarberg S; Agulnik M; Monga V; Milhem M; Parkes A; Robinson S; Okuno S; Attia S; Van Tine BA
Eur J Cancer; 2020 Sep; 137():1-9. PubMed ID: 32712457
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
Karch A; Koch A; Grünwald V
Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
[TBL] [Abstract][Full Text] [Related]
6. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
van der Graaf WT; Blay JY; Chawla SP; Kim DW; Bui-Nguyen B; Casali PG; Schöffski P; Aglietta M; Staddon AP; Beppu Y; Le Cesne A; Gelderblom H; Judson IR; Araki N; Ouali M; Marreaud S; Hodge R; Dewji MR; Coens C; Demetri GD; Fletcher CD; Dei Tos AP; Hohenberger P; ;
Lancet; 2012 May; 379(9829):1879-86. PubMed ID: 22595799
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Martin-Broto J; Stacchiotti S; Lopez-Pousa A; Redondo A; Bernabeu D; de Alava E; Casali PG; Italiano A; Gutierrez A; Moura DS; Peña-Chilet M; Diaz-Martin J; Biscuola M; Taron M; Collini P; Ranchere-Vince D; Garcia Del Muro X; Grignani G; Dumont S; Martinez-Trufero J; Palmerini E; Hindi N; Sebio A; Dopazo J; Dei Tos AP; LeCesne A; Blay JY; Cruz J
Lancet Oncol; 2019 Jan; 20(1):134-144. PubMed ID: 30578023
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup.
Kawai A; Araki N; Hiraga H; Sugiura H; Matsumine A; Ozaki T; Ueda T; Ishii T; Esaki T; Machida M; Fukasawa N
Jpn J Clin Oncol; 2016 Mar; 46(3):248-53. PubMed ID: 26864131
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F
J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
Kim HJ; Kim Y; Lee SJ; Lee J; Park SH
J Gynecol Oncol; 2018 Jan; 29(1):e3. PubMed ID: 29185261
[TBL] [Abstract][Full Text] [Related]
14. The real-life outcome of pazopanib in patients with advanced soft tissue sarcoma: A retrospective cross-sectional study of a Turkish cohort.
Karaağaç M; Sezgin Y; Eryılmaz MK; Araz M; Kaplan MA; Artaç M
J Oncol Pharm Pract; 2020 Oct; 26(7):1657-1666. PubMed ID: 32063110
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
Cesne AL; Bauer S; Demetri GD; Han G; Dezzani L; Ahmad Q; Blay JY; Judson I; Schöffski P; Aglietta M; Hohenberger P; Gelderblom H
BMC Cancer; 2019 Aug; 19(1):794. PubMed ID: 31409302
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
Somaiah N; Van Tine BA; Wahlquist AE; Milhem MM; Hill EG; Garrett-Mayer E; Armeson KE; Schuetze SM; Meyer CF; Reuben DY; Elias AD; Read WL; Chawla SP; Kraft AS
Cancer; 2021 Mar; 127(6):894-904. PubMed ID: 33231866
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib efficacy and toxicity in a metastatic sarcoma cohort: Are Indian patients different?
Sharma A; Vanidassane I; Aggarwal A; Mridha AR; Pandey R; Dhamija E; Barwad A; Rastogi S
Indian J Cancer; 2019; 56(3):207-210. PubMed ID: 31389382
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Nakamura T; Asanuma K; Hagi T; Sudo A
Drug Des Devel Ther; 2020; 14():4215-4220. PubMed ID: 33116409
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
[TBL] [Abstract][Full Text] [Related]
20. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
